Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 2/20 | 0.55 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.55 |
| ▸ | EIF4E | P06730 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | PTPRF | P10586 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19196286 | 0.89 | RAB9A (0.48) | EIF4ENPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL17336635 | 0.83 | NPC1 (0.60) | STIM1ORAI1EIF4ENPC1RAB9A | |
| SCHEMBL12171964 | 0.81 | NPC1 (0.63) | STIM1ORAI1EIF4ENPC1RAB9A | |
| SCHEMBL17336823 | 0.80 | KDM4E (0.64) | EIF4ENPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL17336754 | 0.78 | SMN1; SMN2 (0.71) | NPC1RAB9AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL17348248 | 0.78 | NPC1 (0.56) | EIF4ENPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL19196251 | 0.77 | SMN1; SMN2 (0.65) | EIF4ENPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL24242678 | 0.77 | SMN1; SMN2 (0.51) | EIF4ENPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL23742599 | 0.75 | MAOA (0.60) | EIF4ENPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL12171838 | 0.74 | NPC1 (0.63) | EIF4ENPC1RAB9AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154954-B1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20200347021-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2020-11-05 | — | — | US | disclosed |
| US-10597367-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190016715-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-17 | — | — | US | disclosed |
| US-9969726-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-08-03 | — | — | US | disclosed |
| WO-2015191630-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347021-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | STIM1 2433/4885ORAI1 918/4885EIF4E 3617/4885 |
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | GRM3, GRM2, GRM1 | STIM1 2433/4885ORAI1 918/4885EIF4E 3617/4885 |
| US-20190016715-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | STIM1 2433/4885ORAI1 918/4885EIF4E 3617/4885 |
| US-10597367-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | STIM1 2433/4885ORAI1 918/4885EIF4E 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.